Retour sur lavenir.net
   ELIA GROUP 117.900 € (-0,25 %)     AGEAS 73.350 € (+0,55 %)     SOFINA 243.800 € (+1,67 %)     UMICORE 21.180 € (+3,02 %)     RETAIL ESTATES 62.400 € (+0,32 %)     RECTICEL 12.700 € (-0,31 %)     AB INBEV 64.880 € (+0,50 %)     NYXOAH 1.200 € (+1,18 %)     LOTUS BAKERIES 12 060.000 € (+1,01 %)     ARGENX SE 815.400 € (-3,11 %)     GBL 69.450 € (-0,14 %)     CIE BOIS SAUVAGE 280.000 € (-1,41 %)     ASCENCIO 52.300 € (+0,58 %)     CMB.TECH 17.400 € (+0,23 %)     MONTEA 61.500 € (+0,33 %)     PROXIMUS 5.910 € (+0,17 %)     TINC 10.780 € (-0,19 %)     KBC ANCORA 95.500 € (-1,65 %)     ORANGE BELGIUM 22.200 € (0,00 %)     VAN DE VELDE 29.700 € (-0,67 %)     FLUXYS BELGIUM D 20.500 € (-4,65 %)     WDP 18.750 € (-0,32 %)     CAMPINE 182.500 € (-2,41 %)     BARCO 7.200 € (-0,41 %)     SHURGARD 21.450 € (-1,15 %)     CENERGY 24.040 € (+2,21 %)     SYENSQO 77.600 € (+0,19 %)     DECEUNINCK 2.485 € (+0,81 %)     CFE 10.450 € (-0,95 %)     BREDERODE 99.600 € (-0,40 %)     SIPEF 107.000 € (+0,75 %)     AZELIS GROUP 11.610 € (-0,34 %)     ECONOCOM GROUP 1.290 € (+1,57 %)     ENERGYVISION 17.040 € (-2,07 %)     KINEPOLIS GROUP 48.500 € (-0,31 %)     KBC 124.750 € (-0,87 %)     DEME GROUP 172.400 € (+0,94 %)     VIOHALCO 17.300 € (-1,70 %)     ONWARD MEDICAL 2.575 € (-2,46 %)     AEDIFICA 61.200 € (-1,45 %)     UCB 204.300 € (+1,49 %)     D'IETEREN GROUP 162.900 € (0,00 %)     TUBIZE-FIN 174.400 € (+1,87 %)     QRF 9.900 € (-0,20 %)     HYLORIS 4.200 € (-1,18 %)     BEKAERT 39.250 € (+2,08 %)     TEXAF 37.000 € (-0,54 %)     TITAN S.A. 47.200 € (-1,50 %)     VGP 64.800 € (-1,82 %)     BIOTALYS 1.910 € (-3,54 %)     CARE PROPERTY INV. 12.080 € (+0,67 %)     ACKERMANS V.HAAREN 262.600 € (+0,92 %)     IBA 15.160 € (-1,69 %)     SOLVAY 24.660 € (+1,65 %)     GIMV 46.000 € (+0,44 %)     WERELDHAVE BELGIUM 50.600 € (+1,20 %)     ATENOR 1.060 € (0,00 %)     SOLVAC 88.000 € (+4,14 %)     TESSENDERLO 19.600 € (0,00 %)     INCLUSIO SA/NV 15.800 € (-0,94 %)  
   ASML HOLDING 1 653.000 € (+3,51 %)     MONCEY (FIN.) NOM. 121.000 € (-0,82 %)     ICAPE HOLDING 9.500 € (+2,37 %)     AXA 42.070 € (+0,41 %)     PROSUS 34.500 € (-0,90 %)     ABN AMRO BANK N.V. 41.950 € (+1,21 %)     TELEPERFORMANCE 69.000 € (-2,90 %)     UNILEVER 52.840 € (-0,02 %)     MEDIANTECHNOLOGIES 3.230 € (-10,40 %)     JCDECAUX 24.460 € (-0,89 %)     GROUPE SFPI 1.800 € (-3,23 %)     BIC 64.900 € (-0,15 %)     CREDIT AGRICOLE 16.885 € (-0,21 %)     CAPGEMINI 108.900 € (-2,85 %)     THALES 222.700 € (-1,15 %)     SOITEC 170.700 € (+7,66 %)     2CRSI 26.820 € (+0,68 %)     STMICROELECTRONICS 50.340 € (+6,54 %)     TIKEHAU CAPITAL 15.680 € (+0,51 %)     ENGIE 22.780 € (+1,15 %)     MAGNUM 15.448 € (+1,18 %)     BE SEMICONDUCTOR 204.800 € (+7,00 %)     SOCIETE GENERALE 66.300 € (+0,33 %)     NN GROUP 76.680 € (+0,74 %)     ING GROEP N.V. 30.685 € (+1,44 %)     OVH 16.310 € (-1,21 %)     PRODWAYS GROUP 0.514 € (+2,80 %)     CLARIANE 3.218 € (-5,58 %)     MICHELIN 33.020 € (-0,24 %)     TOTALENERGIES 74.460 € (-0,07 %)     SHELL PLC 42.400 € (+0,38 %)     ARCELORMITTAL SA 57.280 € (+0,95 %)     TECHNIP ENERGIES 28.040 € (-1,20 %)     PHILIPS KON 21.270 € (+0,33 %)     ASM INTERNATIONAL 944.800 € (+5,45 %)     ALPES (COMPAGNIE) 16.800 € (-0,94 %)     ARTMARKET COM 3.340 € (+9,51 %)     STIF 18.990 € (-58,36 %)     SMCP 5.585 € (-3,46 %)     DSM FIRMENICH AG 96.160 € (+0,06 %)     AEGON 7.580 € (+0,69 %)     CEGEDIM 10.840 € (-1,99 %)     DASSAULT AVIATION 282.000 € (-0,28 %)     SEMCO TECHNOLOGIES 50.700 € (+3,68 %)     74SOFTWARE 37.000 € (-2,12 %)     PHARMING GROUP 0.870 € (-1,76 %)     ADP 107.500 € (+3,07 %)     CARREFOUR 15.325 € (-2,08 %)     ACCOR 44.200 € (+0,43 %)     AMOEBA 0.316 € (-1,25 %)     SANOFI 70.810 € (-3,13 %)     COMPAGNIE ODET 1 002.000 € (-0,79 %)     UV GERMI 2.350 € (-3,69 %)     AKZO NOBEL 56.680 € (+2,24 %)     HEXAOM 20.200 € (-2,88 %)     BNP PARIBAS ACT.A 92.060 € (+0,57 %)     MEXEDIA 3.000 € (-3,85 %)     WOLTERS KLUWER 67.820 € (-1,19 %)     CARMILA 14.280 € (-1,65 %)     DBT 0.082 € (-12,39 %)  
News Réglementées
02/10/2026 23:55

IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY

EQS-News: CeraVe / Key word(s): Miscellaneous/Research Update
IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY

02.10.2026 / 23:55 CET/CEST
The issuer is solely responsible for the content of this announcement.


New European research finds 81% recognise the importance of protecting skin beyond UV, yet only 22% use products intended to support the skin barrier

VIENNA, Oct. 2, 2026 /PRNewswire/ -- CeraVe, the skincare brand developed with dermatologists and recommended by more than 80,000 dermatologists worldwide, today reveals new research among 6,000 adults across the UK, France, Germany, Italy and Spain, examining how people understand the skin barrier and respond to everyday environmental pressures.

CeraVe takes to the Vienna hills to launch new research.

The findings reveal a gap between awareness and action. While 90% of adults surveyed are concerned about at least one environmental factor affecting their skin and 81% recognise the importance of protection beyond UV exposure, only 22% use products specifically intended to support the skin barrier.

Nearly half (47%) say their skin is more sensitive than it was five years ago, while 50% report dryness linked to their environment or changing weather. Yet just 10% take additional skincare steps when pollution levels are high, and 55% say skincare must be simple or they will not follow the routine.

The research was unveiled during the European Academy of Dermatology and Venereology Congress in Vienna, where CeraVe brought together dermatology, scientific and brand perspectives to explore the need for clearer skin-barrier education and the science behind safe, efficacious skincare.

"People may experience dryness, tightness or sensitivity without realising these can be linked to the skin barrier. While awareness matters, clear and trusted guidance is the most important factor," said Dr Andrew Park, Board-Certified Dermatologist. "That's why I recommend CeraVe to my patients: developed with dermatologists, formulated with three skin-identical ceramides to help restore and maintain the skin barrier, and rigorously evaluated for safety and efficacy."

For CeraVe, safety and efficacy are considered throughout product development, from identifying a genuine skin-health need through formulation and evaluation. Complete formulations are assessed for safety, efficacy, tolerability and suitability, with scientific and medical input and claims validated by Safety, Claims and Regulatory teams.

"The research shows that people are paying closer attention to their skin, but greater awareness also brings a greater need for clarity and trust," said Gene Colon,  Global Senior Vice President of Medical Relations and Communications at CeraVe. "Our responsibility is to make skin health understandable and accessible, while never compromising on safety and efficacy. As the conversation around skin becomes increasingly complex, we want to give people something simple: credible science, effective skincare and the confidence to make informed choices for their skin."

CeraVe hosts fireside chat with dermatology experts and leadership.

CeraVe booth at EADV Congress 2026 in Vienna.

CeraVe logo.

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/is-skincare-getting-too-complicated-cerave-makes-the-case-for-safety-efficacy-and-simplicity-302897520.html

rt.gif?NewsItemId=EN62643&Transmission_Id=202610021751PR_NEWS_EURO_ND__EN62643&DateId=20261002


02.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2409846  02.10.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière